drugset / Trial / NCT04432233
Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease
NaSingle-groupOpen-labelTreatment
Summary
Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction. Usually, clinicians tended to treat Helicobacter pylori infection after active peptic ulcer disease and related complicaitons getting healed, which spent time and money. This study is designed to evaluate the efficacy and safety of intravenous administration of metronidazole, levofloxacin and esomeprazole triple therapy in the treatment of Helicobacter pylori infection combined with peptic ulcer disease related complications.
Timeline
- Start
- 2020-06-15
- Primary completion
- 2021-04-15
- Completion
- 2021-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esomeprazole | Small molecule | 20 mg | Intravenous |
| Subject | Levofloxacin | Small molecule | 500 mg | Intravenous |
| Subject | Metronidazole | Small molecule | 500 mg | Intravenous |